Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Weighted Average and Diluted) (2021 - 2025)

Cyclerion Therapeutics has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.31 for Q3 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.31 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was -$0.31 (changed N/A YoY), and the annual figure for FY2023 was $3.14, up 410.41%.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.31 at Cyclerion Therapeutics, up from -$0.59 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CYCN hit a ceiling of $5.86 in Q3 2023 and a floor of -$6.16 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.3 (2022), compared with a mean of -$0.42.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 1268.89% in 2022 and later skyrocketed 2542.0% in 2023.
  • Cyclerion Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.24 in 2021, then surged by 33.33% to -$0.16 in 2022, then skyrocketed by 3763.01% to $5.86 in 2023, then plummeted by 105.32% to -$0.31 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.31 (Q3 2025), -$0.59 (Q2 2025), and -$0.57 (Q1 2025) per Business Quant data.